Key result
Transfemoral TAVR was associated with lower 30-day mortality compared to the transapical approach.
Why the study?
Does the transfemoral approach reduce mortality and complications compared to the transapical approach in patients undergoing TAVR with Edwards SAPIEN/SAPIEN XT valves?
Meta-Analysis
Yes
Does the transfemoral approach reduce mortality and complications compared to the transapical approach in patients undergoing TAVR with Edwards SAPIEN/SAPIEN XT valves?
Answers are grounded in this paper and cite their sources.
The transfemoral approach for TAVR is associated with significantly lower 30-day and 1-year mortality, as well as reduced acute kidney injury, compared to the transapical approach.
INTRODUCTION: Both transfemoral (TF) and transapical (TA) routes are utilized for Transcatheter Aortic Valve Replacement (TAVR) using Edwards SAPIEN & SAPIEN XT valves. We intended to perform a meta-analysis comparing the complication rates between these two approaches in studies published before and after the standardized Valve Academic Research Consortium (VARC) definitions. METHODS: We performed a comprehensive electronic database search for studies published until January 2014 comparing TF and TA approaches using the Edwards SAPIEN/SAPIEN XT aortic valve. Studies were analyzed based on the following endpoints: 1-year mortality, 30-day mortality, stroke, new pacemaker implantation, bleeding, and acute kidney injury. RESULTS: Seventeen studies were included in the meta-analysis. Patients undergoing TA TAVR had a significantly higher logistic EuroSCORE (24.6 ± 12.9 vs. 21.3 ± 12.0; P < 0.001). The cumulative risks for 30-day mortality (RR 0.61; 95%CI 0.46-0.81; P = 0.001), 1-year mortality (RR 0.68; 95%CI 0.55-0.84; P < 0.001), and acute kidney injury (RR 0.53; 95%CI 0.38-0.73; P < 0.001) were significantly lower for patients undergoing TF as compared to TA approach. Both approaches had a similar incidence of 30-day stroke, pacemaker implantation, and major or life-threatening bleeding. Studies utilizing the VARC definitions and those pre-dating VARC yielded similar results. CONCLUSION: This meta-analysis demonstrates a decreased 30-day and 1-year mortality in TF TAVR as compared to TA TAVR. Post-procedure acute kidney injury and the need for renal replacement therapy are also significantly lower in the TF group. These differences hold true even after utilizing the standardized Valve Academic Research Consortium criteria.
No takes yet. Share an insight, caveat, or question.
Ghatak et al. (2015) conducted a meta-analysis in Transcatheter Aortic Valve Replacement (TAVR). Transfemoral (TF) TAVR vs. Transapical (TA) TAVR was evaluated on 30-day mortality (RR 0.61, 95% CI 0.46-0.81, p=0.001). Transfemoral TAVR was associated with lower 30-day mortality compared to the transapical approach.
Synapse has enriched 10 related papers. Consider them for comparative context: